首页> 外文期刊>The lancet. Diabetes & endocrinology. >Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (vol 2, pg 369, 2014)

【24h】

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (vol 2, pg 369, 2014)

机译：恩帕格列净与2型糖尿病和慢性肾脏病患者现有抗糖尿病治疗的有效性和安全性：一项随机，双盲，安慰剂对照试验（第2卷，第369页，2014年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet. Diabetes & endocrinology.》 |2015年第3期|共1页
作者
Barnett A. H.; Mithal A.; Manassie J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (vol 2, pg 369, 2014) [J] . Barnett A. H., Mithal A., Manassie J. The lancet. Diabetes & endocrinology. . 2015,第3期

机译：恩帕格列净与2型糖尿病和慢性肾脏病患者现有抗糖尿病治疗的有效性和安全性：一项随机，双盲，安慰剂对照试验（第2卷，第369页，2014年）
2. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: A randomised, double-blind, placebo-controlled trial [J] . BarnettA.H., HuismanH., JonesR., The Lancet . 2013,第9902期

机译：利格列汀用于70岁或以上的2型糖尿病患者，而普通的抗糖尿病药物治疗未得到充分控制：一项随机，双盲，安慰剂对照试验
3. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease [J] . Xin Yang, Bingxuan Zhang, Xiaoguang Lu, BMC Complementary and Alternative Medicine . 2016,第1期

机译：糖肾方对2型糖尿病肾病患者尿和血浆肝型脂肪酸结合蛋白水平的影响：一项多中心，随机，双盲，安慰剂对照试验的事后发现，旨在研究疗效和安全性肾方对2型糖尿病肾病的治疗作用
4. Hierarchy of risk factors for chronic kidney disease in patients with type 2 diabetes mellitus [C] . Bondor Cosmina Ioana, Kacso Ina Maria, Lenghel Alina Ramona, 2012 IEEE 8th International Conference on Intelligent Computer Communication and Processing. . 2012

机译：2型糖尿病患者慢性肾脏病危险因素的层次
5. The Use of Bayesian Principles to Predict the Optimal Revisit Interval and the Causal Relationship between Revisit Intervals and Chronic Kidney Disease for Medicare Patients with Type II Diabetes [D] . Lasway, Annie Enikunda. 2020

机译：贝叶斯原则的利用预测II型糖尿病患者Revisit间隔和慢性肾病的最佳Revisit区间和因果关系
6. Rationale and design of the EMPA-ELDERLY trial: a randomised double-blind placebo-controlled 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes [O] . Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, 2021

机译：Empa-Resion试验的理由和设计：随机双盲安慰剂控制52周的临床试验的钠葡萄糖Cotoransporter-2抑制剂Empagliflozin患者2型糖尿病患者的疗效和安全性
7. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease [O] . Xin Yang, Bingxuan Zhang, Xiaoguang Lu, 2016

机译：糖肾方对2型糖尿病肾病患者尿和血浆肝型脂肪酸结合蛋白水平的影响：一项多中心，随机，双盲，安慰剂对照试验的事后发现，旨在研究疗效和安全性肾方对2型糖尿病肾病患者的作用

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号